The top 500 list announces another record high for medicine, but these white horses have fallen the most.

According to this year's list, the big health sector grew significantly, becoming the top 500 companies for the first time, surpassing last year's first and second-ranked advanced manufacturing and real estate, and up 27 companies from last year to 93, accounting for 18% of the list.
of the 120 new companies listed this year came from Big Health and Advanced Manufacturing.
the top three in this year's big health industry are Hengrui Pharmaceuticals, Meirui Medical and Pharmaceutical Mingkangde, valued at 495 billion yuan, 452 billion yuan and 265 billion yuan, respectively, TOP10 enterprises also Zhifei Bio, Pharmaceutical Ming Bio and Love Er ophthalmology, these three enterprises are worth more than 200 billion yuan, and then for Hansen Pharmaceuticals, Baiji Shenzhou, Yangzijiang Pharmaceuticals and China Biopharmaceuticals, its value is more than 130 billion yuan, this number is also the threshold of the big health industry TOP10.
Big Drug Companies: White Horse Fall Although this year's big health industry performance, also for the first time became the number one industry on the list, but the former large traditional pharmaceutical companies in the industry-wide list, but it is almost collective downward trend.
The biggest fallers in the big health sector this year were Jimin Credibility, which fell 210 places to 418th place, in addition, Correctional Pharmaceuticals, Taibang Bio, Tiansli Pharmaceuticals and Colum Pharmaceuticals all fell by 1 71, 167, 146 and 135, even if such as Hengrui Pharmaceuticals, Hansen Pharmaceuticals, Stone Pharmaceuticals Group, China's biopharmaceutical industry head companies, this year's ranking has dropped several or even dozens.
Hengrui first entered China's private enterprise TOP10 last year, this year fell to 14th place, is a traditional large pharmaceutical companies in a more stable performance, while several leading enterprises fell in the 20th and 30th place.
is true, this is related to China's own fast-growing economy, while the rise of head companies in the Internet, finance, e-commerce and manufacturing has also led to a decline in the pharmaceutical industry as a whole.
but I have to admit that in the past few years, China's pharmaceutical industry has under changed, the industry needs to experience a short period of pain, especially in the policy-influenced generic drugs, traditional chinese medicine-based large enterprises.
This year's biggest decline in Jimin credibility to "golden water treasure", "wake up quiet", "Huang's sound pill" as the core products, but in the era of innovation torrent, the enterprise is also turning part of the focus to innovative drugs, this year in Wuxi High-tech District to open a large molecule biopharmaceus research and development, production headquarters, has been established in Shanghai Zhangjiang Research Institute, in the development and commercial production of large molecular drugs invested heavily.
Tiansli, Colum and other enterprises are also in the innovative drug layout, but is still in the investment period.
Telling the story of innovation may no longer be the strength of these traditional big businesses, except for Hengrui, which has thrown its rivals a few streets away with six or seven approved new drugs, and it's hard to say who has been a great success.
500 companies, East China Pharmaceuticals and Qilu Pharmaceuticals, did not appear on the list this year.
China Biopharmaceuticals, Stone Pharmaceutical Group and a few other enterprises have been approved one or two innovative drugs, but the real harvest period is still some time away, the pain of industrial transformation will continue for some time.
exceptions, such as Huahai Pharmaceuticals, a traditional big drug company with the advantage of raw materials, which has grown by 72 this year.
Innovation Pharmaceutical Company: Straight Up to the Cloud Junshi Bio is the fastest-growing company this year, rising by half a list span, from 400 to 147th place, followed by Re-Ding, up 244 places , rising to 199th place, first-timer Consino moved straight up to 165th, Xinda rose 110 places to 127th, and Baiji Shenzhou rose directly to top10 in the big health industry.
These familiar star innovative pharmaceutical companies, this year's performance is particularly bright, coupled with vaccines, CRO, IVD enterprises, these four sub-sectors of the company is this year's pharmaceutical industry "excellent students" mainstream, including Tag Pharmaceuticals, Kanglonghuacheng, Kailaiying, Beida Pharmaceuticals, Zhao Yanxin Pharmaceuticals, Shenzhou Cells, Zeyu Pharmaceuticals and so on.
vaccine enterprises this year's results are also the rise of qi brush, Wantay Bio and Consino first on the list will rush into more than 100 positions, Zhifei Bio rose 53 places, into the pharmaceutical enterprise TOP5, Kantai Bio, Hualan Bio also rose sharply, in the pharmaceutical enterprise TOP10 edge wandering, Watson Bio, Wantai Bio have entered the pharmaceutical enterprise TOP20.
with the help of capital market reforms, the new crown outbreak, and so on, these vaccine companies are very bright performance.
In recent years, pharmaceutical policy reforms, especially the opening of the Hong Kong Stock 18A and The Science and Technology Board, have created a number of innovative pharmaceutical companies, and last year and this year in the list of innovative pharmaceutical companies are benefiting from the opening of the capital market.
Especially this year's fastest-growing Junshi Bio, following the listing in Hong Kong stocks, in July this year, Junshi Bio landed on the board, the opening price of 216 yuan, up 289% from the issue price, the market value of the day more than 145 billion yuan.
as of the end of November, the market capitalisation of Junshi Biotech's board was still over $60 billion, compared with HK$36.6 billion in Hong Kong shares.
as the first innovative pharmaceutical company to launch a domestic PD-1, Junshi Bio achieved a wave of growth this year with the help of new crown-and-antibodies and a deal with Lilly.
Consino is also using the concept of the new crown vaccine all the way up, less than a decade after the establishment of Cinda launched four biological drugs, Baiji Shenzhou is gradually entering the harvest period.
With the Hong Kong stock 18A, the implementation of the New Deal, the first two batch of innovative pharmaceutical companies gradually into the harvest period, a number of new faces in these two years to the front desk, while the valuation of the capital market to give them a place in the top 500 list, and even beyond the old pharmaceutical companies, to the domestic first echelon.
Innovating pharmaceutical companies originating in China are becoming an increasingly important industrial force in China's pharmaceutical industry, but whether the concept of innovative drugs is overheating and whether there is a bubble is a major controversy in the industry.
at the recent 2020 China Pharmaceutical Industry Scientists entrepreneurs' investor conference, Defoe Capital Chairman and CHIEF Executive Officer Li Zhenfu said that today's pharmaceutical industry is "very divided", with different labels can get a completely different valuation, the value of innovation is determined to deviate from clinical value.
under this differentiation and label, who is the real value of pharmaceutical companies, and who can become China's first trillion-dollar market value of pharmaceutical companies?